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Abstract: Canine cutaneous epitheliotropic T-cell lymphoma (CETL) and immune-mediated T-cell
predominant dermatoses (IMD) share several clinical and histopathological features, but differ
substantially in prognosis. The discrimination of ambiguous cases may be challenging, as diagnostic
tests are limited and may prove equivocal. This study aimed to investigate transcriptional differences
between CETL and IMD, as a basis for further research on discriminating diagnostic biomarkers.
We performed 100bp single-end sequencing on RNA extracted from formalin-fixed and paraffin-
embedded skin biopsies from dogs with CETL and IMD, respectively. DESeq2 was used for principal
component analysis (PCA) and differential gene expression analysis. Genes with significantly
different expression were analyzed for enriched pathways using two different tools. The expression
of selected genes and their proteins was validated by RT-qPCR and immunohistochemistry. PCA
demonstrated the distinct gene expression profiles of CETL and IMD. In total, 503 genes were
upregulated, while 4986 were downregulated in CETL compared to IMD. RT-qPCR confirmed
the sequencing results for 5/6 selected genes tested, while the protein expression detected by
immunohistochemistry was not entirely consistent. Our study revealed transcriptional differences
between canine CETL and IMD, with similarities to human cutaneous lymphoma. Differentially
expressed genes are potential discriminatory markers, but require further validation on larger
sample collections.
Keywords: Canis lupus familiaris; dog; skin disease; cutaneous T-cell lymphoma; Lupus erythemato-
sus; cytotoxic dermatitis; RNA sequencing; FFPE tissue; transcriptome
1. Introduction
Canine cutaneous epitheliotropic T-cell lymphoma (CETL) is a neoplastic skin disease
of dogs, in which the neoplastic T lymphocytes have a specific tropism for the epithelium of
haired skin and mucocutaneous junctions [1–3]. The etiology and pathogenesis of CETL are
largely unclear [1,2]. T lymphocyte-driven immune-mediated cytotoxic dermatitis (IMD)
is a reaction pattern, in which inflammatory T-cells target the keratinocytes of the skin
and mucocutaneous junctions [1,4–6]. The IMD reaction pattern is recognized in various
cutaneous forms of canine lupus erythematosus (LE). A unifying feature of the different
cutaneous LE forms is the deposition of immunoglobulins and complement factors in the
basement membrane zone, which initiates a cytotoxic T-cell reaction restricted to the basal
cell layer [4]. Furthermore, IMD is seen in canine panepidermal cytotoxic dermatitis (PCD),
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in which cytotoxic T lymphocytes are triggered by exogenous agents (e.g., drugs, viral
infection) to react against epidermal keratinocytes in all layers of the epidermis [1,5]. Other
cases of canine IMD remain idiopathic [1,5].
Clinically, canine CETL and IMD share several features, in particular in the first
months of the disease. Both may manifest with variably pruritic erythematous macules,
papules, plaques, erosions, ulcerations, crusts, alopecia, scaling and depigmentation af-
fecting haired skin, mucocutaneous junctions, footpads and mucous membranes [2,4,7–9].
CETL is a disease of middle-aged to old dogs with a mean age of onset of 10–11 years [2,8].
IMD can occur in dogs of all ages, but some forms predominantly affect middle-aged to old
dogs (e.g., old-dog erythema multiforme; generalized discoid Lupus erythematosus) [1,4,9].
The most important clinical differences between CETL and IMD are the clinical course and
the prognosis. In CETL, the progression of skin lesions and metastasis to lymph nodes
is a common finding, even after treatment with chemotherapy and immunomodulatory
drugs [2,7]. A large retrospective study comprising 148 cases undergoing different treat-
ment modalities reported a median survival time of 264 days (range 5–2992 days) [8]. IMD
have a better prognosis, since lesions frequently respond to immunomodulatory treatment
or may even resolve spontaneously, particularly when the trigger can be removed [4,6].
The gold standard for the diagnosis of IMD and CETL is the histopathological examina-
tion of skin biopsies of affected dogs. In both diseases, T lymphocytes—neoplastic in CETL,
reactive in IMD—infiltrate the epidermis/mucosal epithelium, the adnexal structures and
the dermis to variable extents [1,2,4–7]. Around 25% of CETL cases show pathognomonic
Pautrier’s microabscesses [2]. In IMD, the inflammation is centered either on the basal
cell layer of the epidermis and hair follicle epithelium (“interface”), and is combined with
a lichenoid inflammation in LE cases, or presents with transepithelial infiltration and
keratinocyte apoptosis in all epidermal layers in PCD cases [1,4–6].
Early-stage CETL lesions with low to moderate numbers of well-differentiated and
solely intraepithelial neoplastic lymphocytes may be difficult to discriminate from cell-rich
IMD lesions in routine histopathology slides [1,6]. In assessing the biopsies submitted
to our dermatopathology service, about 3–5% of the total of CETL and IMD cases have
ambiguous histopathological features, requiring additional lymphocyte clonality testing
by PCR (PARR). With this test, the lymphocytic infiltrate can be classified as neoplastic
if monoclonal vs. inflammatory if polyclonal [10]. However, there is the risk of incon-
clusive results, as PARR is not sensitive enough to detect small numbers of monoclonal
lymphocytes in subtle CETL lesions, in particular when whole-biopsy paraffin sections are
used, and/or a polyclonal background caused by secondary inflammation obscures the
monoclonal signal [10]. Conversely, clonal expansion may occur in reactive inflammatory
processes [10]. Supplemental immunohistochemical analyses (IHC) are of limited value,
as the infiltrate consists mostly of cytotoxic T lymphocytes in both disease types [4,7,9].
Discriminatory immunohistochemical markers as used in human medicine either do not
work on canine formalin-fixed and paraffin-embedded (FFPE) tissues, are not sensitive
enough or are completely lacking [7,11]. In such equivocal cases, a reliable diagnosis is not
possible at the time of biopsy analysis. As a consequence, only the clinical course and a
possible follow-up biopsy will result in a definite diagnosis, with the risk of inappropriate
treatment and impaired disease outcome in the time of diagnostic uncertainty.
For the discovery of markers reliably discriminating ambiguous CETL and IMD cases,
the knowledge of molecular differences between neoplastic and inflammatory processes is
crucial, but currently not sufficient. To expand the state of knowledge, our study aimed
to investigate the transcriptional differences between canine CETL and IMD, as a basis
for the further identification of candidate biomarkers discriminating between neoplasia
and inflammation. We hypothesized that the transcriptome profiles of CETL and IMD
biopsy samples are significantly different, and single differentially expressed genes and/or
their proteins might serve as discriminating biomarkers. Encouraged by previous studies,
in which comparative gene expression analyses have been performed on canine FFPE
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samples [12,13], we addressed our aims by global mRNA sequencing using archival FFPE
biopsy samples from dogs afflicted by either CETL or IMD.
2. Materials and Methods
Ethics statement: All samples used in this retrospective study were archival biopsy
samples taken and submitted to our institution for diagnostic purposes. By submission, the
owner gave their consent for the future use of the tissues for research purposes. This proce-
dure complies with the institutional ethical requirements, and obviates the requirement of
animal experiment permission.
Study samples and disease characterization: Twenty formalin-fixed and paraffin-embedded
(FFPE) biopsy samples from dogs with the histological diagnosis of immune-mediated
dermatitis (IMD) (n = 11) and cutaneous epitheliotropic T-cell lymphoma (CETL) (n = 9)
were selected from our institutional 2013–2017 archive. Of the eleven IMD cases, four
were clinically and histopathologically compatible with lupus erythematosus (LE), and
seven with panepidermal cytotoxic dermatitis (PCD). Inclusion criteria for all cases were
the presence of a mild intraepithelial lymphocytic infiltrate with only minimal dermal
involvement, but nevertheless allowing a histopathological diagnosis, and the availability
of at least three punch biopsies from haired skin. Anamnesis and clinical follow-up data
were retrieved from the referring veterinarians using a questionnaire.
From all FFPE blocks 3 µm sections were mounted on glass slides and stained with
hematoxylin and eosin (H&E) and the periodic acid–Schiff reaction (PAS) according to
routine protocols. The sections were evaluated blindly by one author, a board-certified vet-
erinary pathologist, by assessing several histological parameters as listed in the supporting
material (Table S2). Fungal infections were excluded in all cases using the PAS reaction.
To confirm the classification into the neoplastic and the inflammatory groups, re-
spectively, a PCR for antigen receptor rearrangement (PARR) was performed. For this
purpose, genomic DNA was extracted from the FFPE material using seven 16 µm sections
each according to manufacturer’s instructions (QIAamp DNA FFPE Tissue Kit, QIAGEN,
Hombrechtikon, Switzerland) with the exception that tissue lysis with proteinase K was
performed overnight. DNA was quantified using the NanoDrop 1000 Spectrophotometer
(NanoDrop Technologies, Wilmington, NC, USA). The amplification of the TCRγ locus
was performed on a 96-well VeritiTM Thermal Cycler (Applied Biosystems, Rotkreuz,
Switzerland) in duplicate as previously described [14]. The PCR product was visualized
on the Fragment AnalyzerTM Automated CE System (Agilent, Basel, Switzerland) using
the dsDNA 905 Reagent Kit, 1–500 bp (Agilent, Basel, Switzerland) according to manufac-
turer’s instructions. Two cases had a negative PARR result (no amplified sequences), but
had clear-cut histopathological lesions and a compatible clinical disease course, enabling a
reliable disease classification.
RNA extraction: Total RNA was extracted from 10 to 16 µm sections (15–30 per sample)
of the FFPE tissue using the RNeasy FFPE Kit (QIAGEN, Hombrechtikon, Switzerland)
according to manufacturer’s instructions. Residual genomic DNA was removed from the
total RNA with a DNase treatment step according to the manufacturer’s protocol. The
quantity and quality of the extracted RNA was analyzed using a NanoDrop 1000 Spec-
trophotometer (NanoDrop Technologies, Wilmington, NC, USA). RNA integrity (RIN) was
assessed on a Fragment AnalyzerTM Automated CE System (Agilent, Basel, Switzerland).
RNA samples were aliquoted and stored at −80 ◦C until further use.
RNA Sequencing: From the twenty cases, five cases with RIN values < 2.5 (range of
all cases: 1.2–10.0), and/or with a Nanodrop A260/280 < 1.85 ratio (range: 1.79–2.03),
were excluded, resulting in fifteen samples (CETL n = 6, PCD n = 6, LE n = 3) subjected to
RNA sequencing (RNA-seq). Library preparation was performed without further RNA
fragmentation with the SMARTer Stranded Total RNA-Seq Kit v2—Pico Input Mammalian,
according to manufacturer’s instructions (Takara Bio, Saint-Germain-en-Laye, France). This
protocol includes a ribosomal RNA depletion by ZapR v2 in the presence of mammalian-
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specific R-Probes. Subsequently, the libraries were sequenced on two lanes with 100 bp
single-end sequencing cycles on an Illumina HiSeq 3000 (Illumina, Zurich, Switzerland).
Raw data analysis: The Illumina BCL output files with base cells were converted into
the FASTQ format and demultiplexed. Data are available from the European Nucleotide
Archive (accession no. PRJEB31872). Raw reads were filtered for low quality sequences
and trimmed from adapters using the FastQC version 0.11.7 [15]. All reads that passed
quality control were aligned to the dog reference genome CanFam3.1 using STAR aligner
version 2.6.0c [16]. Reads were aligned using the following parameters: –outFilterType
BySJout; –outFilterMultimapNmax 50; –alignSJoverhangMin 1; –outFilterMismatchNmax
2; –outFilterMismatchNoverLmax 0.04; –alignIntronMin 20; –alignIntronMax 1,000,000;
–alignMatesGapMax 1,000,000. Aligned reads were counted using HTseq version 0.9.1 [17],
and a NCBI transcript database (version 104) derived from the CanFam3.1 dog genome
assembly. Quality control, mapping and feature counting were performed on UBELIX
(http://www.id.unibe.ch/hpc), the HPC cluster at the University of Bern, and the necessary
tools were loaded from Vital-IT.
Differential expression analysis: The DESeq2 package was used to read the HTseq count
data [18]. A filtering step for low/non-expressed (counts 0/1) genes was done. For
visualization, a principal component analysis (PCA) was performed with the logarithm
transformed count data. Because there was no separation between PCD and LE cases in
the PCA plot (Figure 1), we decided to perform the following experiments and analyses
with only two groups, CETL and IMD, respectively, without the further subgrouping of the
IMD cases. We also used Cook’s distance calculation with default DESeq2 function. Cook’s
distance is a measure of how much a sample is influencing the fitted coefficients for a gene,
and a large value of Cook’s distance indicates an outlier count. Subsequent differential
gene expression analysis was performed with DESeq2 version 1.6.3 using the IMD group
as control. DESeq2 applies a generalized linear model (GLM) to count data assuming a
negative binomial distribution. Transcripts were considered differentially expressed with a
Benjamini and Hochberg false discovery rate (FDR) of <0.01 (log2 fold-change (log2FC)
<−0.58 and >0.58; p < 0.05).
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Pathway and gene enrichment analysis: To look for enriched pathways and gene networks
among the differentially expressed genes, we applied two different enrichment analysis
tools, Ingenuity Pathway Analyis (IPA®, QIAGEN, Hombrechtikon, Switzerland) and
KOBAS 3.0 [19]. The latter uses pathways from the KEGG database, and gene ontologies
from the GO database. Because of the asymmetric distribution of the DESeq output in terms
of gene numbers and log2FC between up- and downregulated genes, we performed two
separate enrichment analyses, one including all genes with a logFC >1.5 (log2FC > 0.58;
p < 0.05), and one including all genes with a logFC < −1.5 (log2FC < −0.58; p < 0.05),
respectively, in the CETL group, as described previously [20].
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RT-qPCR: In order to validate the RNA-seq results, and to assess the value of certain
genes as a discriminating marker, RT-qPCR was performed using RNA from the 15 se-
quenced samples. We selected five candidate genes upregulated in the CETL group (CD5,
IL2RB, ILK, ITGB7 and TCF7) that have already been described to play a role in human
cutaneous T-cell lymphomas and other forms of cancer [21–28]. Although not differentially
expressed in the RNA-seq experiment, FOXP3, a transcription factor of regulatory T-cells,
was selected for RT-qPCR due to its previously described association with several human
skin diseases, including mycosis fungoides (MF) [29–32]. Extracted total RNA (1–2 µg
per sample) was reverse transcribed using the GoScript™ Reverse Transcription Mix with
Random Primers (Promega Corporation, Dübendorf, Switzerland), according to manu-
facturer’s specifications. Primers for genes of interest (CD5, FOXP3, IL2RB, ILK, ITGB7,
TCF7) were designed using Primer3Plus [33]. Primers for reference genes (RPL8, RPS19)
were chosen among seven genes previously described to be stably expressed in canine skin
(GUSβ, CZZ1, RPL8, RPL32, RPS5, RPS18, RPS19) using the GeNorm algorithm [12,34–37].
Primer sequences are listed in Table 1.
Table 1. Primer sequences for quantitative real-time qPCR.
Gene Accession Forward Reverse Product Size (bp)
CCZ1 XM_536878.6 GCAGGAAGGGATTCTCCAG GGTCCAGTAAGAAATCTTCCATAA 74
GUSβ NM_001003191.1 GTGCTGGATCAGAAACGCAA CTTTGGGTTGTCTCTGGCGA 136
RPL8 XM_532360 CCATGAATCCTGTGGAGC GTAGAGGGTTTGCCGATG 64
RPL32 XM_848016 TGGTTACAGGAGCAACAAGAAA GCACATCAGCAGCACTTCA 100
RPS5 XM_533568 TCACTGGTGAGAACCCCCT CCTGATTCACACGGCGTAG 141
RPS18 XM_532106 TGCTCATGTGGTATTGAGGAA TCTTATACTGGCGTGGATTCTG 116
RPS19 XM_533657 CCTTCCTCAAAAAGTCTGGG GTTCTCATCGTAGGGAGCAAG 95
CD5 XM_022405839.1 CTTAGGCTGGCCTTGAAGCT ACACTGGTGTTGCAGTTGGA 143
FOXP3 NM_001168461.1 AAATTCCACAACATGCGCCC AGGCAAACATGCGTGTGAAC 124
IL2RB NM_001286851.1 TCCTGTGAGCTGCTCCCTAT ATCCTCCACCTCTCCCCTTC 137
ILK XM_022407778.1 CACGGTTAGGGGAGTGTGTC CCGTGTGGCAAGTGACAAAG 163
ITGB7 XM_022411473.1 GACTCCAGCAACGTGGTACA CCCTCTTCTCAGGATCCCCA 136
TCF7 XM_022425289.1 GCAGAGACTTTTCCCCGACA GCATGAGCAGATTGAAGGCG 116
Each primer pair was tested in a preliminary RT-qPCR assay for efficiency using a
standard curve of six serial dilutions of a balanced mixture of cDNA from all samples. A
negative control lacking any cDNA sample was included for each primer pair standard
curve validation. Primer efficiencies ranged from 94 to 109%. Preliminary and definite
RT-qPCR assays were performed with a 10 ng cDNA template in a 15 µl reaction using
Fast Start Universal SYBR Green Master (Rox) (Roche Diagnostics, Rotkreuz, Switzerland).
Each reaction was run in triplicate in three independent runs on a 7500 Fast Real-Time PCR
System (Applied Biosystems, Rotkreuz, Switzerland) with the following conditions: 10 min
95 ◦C for activation, 40 cycles of 10 s 95 ◦C and 30 s 58 ◦C for amplification, completed
by a dissociation cycle of 15 s 95 ◦C, 30 s 60 ◦C and 15 s 95 ◦C. Data were collected and
processed with the 7500 Software v2.3. Standard curve and ∆∆CT-analysis (Pfaffl method)
was performed in Excel. Differences in relative mRNA expression between CETL and IMD
cases were calculated for each gene with a Man–Whitney-U test using GraphPad Prism
6.00 for Windows (GraphPad Software, LaJolla, CA, USA).
Immunohistochemistry (IHC): For the validation of candidate markers on the protein
level, IHC for TCF7 and FOXP3 was performed on all samples submitted to gene expression
analysis and the remaining samples with insufficient RNA quality (n = 20). IHC validation
was limited to these two proteins due to a lack of antibodies for the other proteins working
on canine FFPE tissue.
From all cases 3 µm tissue sections were mounted on glass slides, deparaffinized and
rehydrated. Antigen retrieval was performed in citrate buffer (pH 6.0) for 20 min in a
pressure cooker (107 ◦C, 3 bar). Nonspecific antibody binding was blocked by incubation
with 10% normal goat serum in phosphate buffered saline (PBS) for 30 min, followed by
primary antibody incubation (rabbit monoclonal anti-TCF7, diluted 1:100 in PBS (C.725.7,
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ThermoFisher Scientific, Reinach, Switzerland) and rat monoclonal anti-FOXP3, diluted
1:100 in PBS (FJK-16s, eBioscence, San Diego, CA, USA)) overnight at 4 ◦C. Endogenous
peroxidase activity was blocked by incubation in 3% H2O2 for 15 min. After incubation
for 30 min at room temperature (RT) with the pre-diluted biotinylated goat anti-mouse
IgG secondary antibody (Agilent Technologies AG, Basel, Switzerland) and biotinylated
goat anti-rat IgG (Vector laboratories, Burlingame, CA, USA), respectively, streptavidin-
biotin-peroxidase (Agilent Technologies AG, Basel, Switzerland) was applied for 30 min
at RT. The reaction was visualized by AEC substrate-chromogen (Agilent Technologies
AG, Basel, Switzerland) application for 10 min. Counterstaining was performed using
hematoxylin. A canine lymph node from our pathology archive served as positive control.
As negative control, the primary antibody was replaced by monoclonal rabbit IgG serum
(ab172730, abcam, Cambridge, UK) and monoclonal rat IgG2a kappa isotype control (eBR2a,
eBioscence, San Diego, CA, USA), respectively, in equal dilutions. The specificity of the
FOXP3 antibody in canine tissue has been shown previously [38], and the specificity of the
TCF7 antibody was confirmed by western blot in the course of this study (Appendix A).
In addition, CD3 immunostaining using the LN10 clone (Leica Biosystems, Muttenz,
Switzerland) in a 1:100 dilution on 3 µm tissue sections was performed on the BOND-III system
(Leica Biosystems, Muttenz, Switzerland), complying with manufacturer’s instructions.
For evaluation, ten photomicrographs each of epidermis, dermis and adnexal struc-
tures in 40× magnification were taken from every stained section with a ProgRes®C5
microscope camera (Jenoptik, Jena, Germany). Labeled cells within the epidermis, dermis,
adnexa, periadnexal tissue were counted manually using the MultiPoint tool of the ImageJ
program 2018 [39]. The mean percentage of TCF7-positive and FOXP3-positive T-cells was
calculated by dividing the number of CD3-positive cells by the number of TCF7-positive or
FOXP3-positive cells, respectively, each counted in ten photomicrographs. This percentage
was calculated for the whole skin biopsy, for epidermis and adnexa combined (“epithe-
lium”), and for dermis and periadnexal tissue combined (“dermis”). The mean percentage
was compared between CETL and IMD cases using a Man–Whitney-U test. Statistical




Signalment, overall survival time and the results of the PARR of the 20 cases are
summarized in Table 2. Among the nine dogs with CETL, three were Cocker Spaniels,
while other breeds were not overrepresented in both disease groups. The mean age at the
time of diagnosis was 10 years 4 months (7 y 7 m to 13 y 9 m) in the CETL group, and
7 years 7 months (2 y 3 m to 11 y 8 m) in the IMD group. The median overall survival
time of CETL patients was 166 (6–277) days. All CETL patients were euthanized due to
the worsening of the skin lesions. At the end of the study, 6 out of 11 IMD cases were
still alive, with either cured or therapeutically controlled disease (241–1086 days after
diagnosis). One dog with IMD died after 1324 days due to reasons unrelated to the skin
disease. Four panepidermal cytotoxic dermatitis (PCD) cases and one lupus erythematosus
(LE) case with severe exfoliation required early euthanasia due to the severity of skin
lesions (2–78 days after diagnosis). More details on clinical and histopathological findings
are available in the Supplementary Materials (Tables S1 and S2).
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PARR 2 Tests Applied
1 IMD (PCD) Jack Russel Terrier M 10 y 10 m 78 polyclonal RNA-seq, RT-qPCR, IHC
2 CETL Mixed F 7 y 9 m 166 clonal IHC
3 CETL Cocker Spaniel MC 7 y 7 m 230 clonal RNA-seq, RT-qPCR, IHC
4 CETL Pyrenean Shepherd FS 12 y 277 clonal RNA-seq, RT-qPCR, IHC
5 IMD (PCD) Briard M 10 y 2 m 1324 polyclonal RNA-seq, RT-qPCR, IHC
6 CETL West HighlandWhite Terrier FS 11 y 8 m 187 negative IHC
7 IMD (PCD) AmericanStaffordshire Terrier MC 11 y 8 m 54 polyclonal RNA-seq, RT-qPCR, IHC
8 CETL Cocker Spaniel FS 13 y 9 m 179 clonal RNA-seq, RT-qPCR, IHC
9 CETL Mixed MC 11 y 3 m 18 clonal RNA-seq, RT-qPCR, IHC
10 CETL Cocker Spaniel FS 11 y 1 m 6 clonal IHC
11 CETL Golden Retriever F 9 y 2 m 57 clonal RNA-seq, RT-qPCR, IHC
12 IMD (PCD) Shetland Sheepdog F 10 y 7 m alive polyclonal RNA-seq, RT-qPCR, IHC
13 IMD (LE) Border Collie MC 5 y 3 m alive negative RNA-seq, RT-qPCR, IHC
14 IMD (PCD) Podenco Canario FS 9 y 8 m 45 polyclonal IHC
15 CETL Boxer M 8 y 8 m 134 clonal RNA-seq, RT-qPCR, IHC
16 IMD (LE) Magyar Vizsla F 2 y 3 m 2 polyclonal RNA-seq, RT-qPCR, IHC
17 IMD (PCD) Great Pyrenees FS 5 y 11 m alive polyclonal RNA-seq, RT-qPCR, IHC
18 IMD (LE) Rhodesian Ridgeback M 2 y 6 m alive polyclonal RNA-seq, RT-qPCR, IHC
19 IMD (PCD) Yorkshire Terrier FS 11 y 2 m alive polyclonal RNA-seq, RT-qPCR, IHC
20 IMD (LE) Tervuren M 2 y 3 m alive polyclonal IHC
1 M, male; MC, male castrated; F, female; FS, female spayed. 2 Negative, no amplicon detected.
3.2. RNA Sequencing and Raw Data Analysis
Single-end sequencing of the fifteen RNA libraries produced a mean number of
30 million (M) reads per sample on average (range: 25–36 M). The mean percentage of
reads uniquely mapped to the genome was 82.6%, ranging from 75.5 to 86.9%. Among
those, 29.7% on average mapped to the annotated canine transcriptome (range: 21.6–39.1%),
resulting in 7 M counts per sample on average (Table S3).
3.3. Differential Gene Expression Analysis
The principal component analysis of the differentially expressed genes illustrates a
clear separation of CETL and IMD cases with respect to gene expression (Figure 1). Six
of the nine IMD cases clustered together, while three IMD cases were more distantly lo-
cated. Cook’s distance test showed no outliers or any sample that was highly influential
(Figure S1). As there was clustering of LE and PCD cases in this PCA, and because histo-
logically, ambiguous CETL lesions may be akin to both LE and PCD lesions, we decided to
use all IMD cases as one group for the subsequent analyses. Differential gene expression
analysis resulted in 5489 differentially expressed genes (Table S4). Among those, 503 genes
were upregulated, while 4986 genes were downregulated in CETL samples compared to
IMD samples. The related MA plot is shown in Figure 2.
3.4. Pathway and Gene Enrichment Analysis
Enrichment analysis applied on the 503 genes with significantly higher expression in
CETL samples resulted in 28 enriched IPA pathways, 1 KEGG pathway and 83 GO terms
(p < 0.05) (Table S5). When all 4986 genes with significantly lower expression in CETL
samples were used as input, 55 IPA pathways, 5 KEGG pathways and 61 GO terms were
identified (p < 0.05) (Table S6). The top three enriched pathways and GO terms, respectively,
for all three databases used are listed in Tables 3 and 4. Information on genes involved in these
pathways and gene networks is available in the supporting material (Tables S5 and S6).
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Table 3. Top three enriched pathways and GO terms, respectively, among genes with significantly
higher expression in CETL samples resulting from enrichment analyses with KOBAS 3.0 and IPA.
Pathway Enrichment Analysis Tool Database p-Value
EIF2 signaling IPA IPA 1.66 × 10−7
ILK signaling IPA IPA 1.02 × 10−6
Integrin signaling IPA IPA 9.55 × 10−5
Ribosome KOBAS KEGG 1.87 × 10−6
Cytosolic ribosome KOBAS GO 1.87 × 10−6
Ribosomal subunit KOBAS GO 1.87 × 10−6
Focal adhesion KOBAS GO 1.87 × 10−6
Table 4. Top three enriched pathways and GO terms, respectively, among genes with significantly lower expression in CETL
samples resulting from enrichment analyses with KOBAS 3.0 and IPA.
Pathway Enrichment Analysis Tool Database p-Value
GABA receptor signaling IPA IPA 5.01 × 10−12
Cellular effects of sildenafil (Viagra) IPA IPA 8.51 × 10−9
Glutamate receptor signaling IPA IPA 8.51 × 10−8
Olfactory transduction KOBAS KEGG 2.01 × 10−43
Neuroactive ligand–receptor interaction KOBAS KEGG 2.70 × 10−5
Nicotine addiction KOBAS KEGG 1.39 × 10−3
Transmembrane signaling receptor activity KOBAS GO 2.86 × 10−9
Signaling receptor activity KOBAS GO 2.86 × 10−9
G-protein coupled receptor activity KOBAS GO 2.86 × 10−9
3.5. RT-qPCR
For five out of the six selected genes, the relative mRNA expression levels identified
by RT-qPCR of the CETL and IMD samples were compatible with the RNA-seq results
(Figure 3). TCF7, ITGB7, ILK and IL2RB were significantly upregulated (p < 0.05). Consis-
tent as well with the RNA-seq results, FOXP3 mRNA levels were not significantly different
in the RT-qPCR (p = 0.99). Differences in CD5 expression detected in the RNA-seq, however,
could not be verified in RT-qPCR (p = 0.11). No significant difference in the mRNA levels
was detected between the PCD and LE cases for all six genes tested (Figure S2).
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4. Discussion
Here, we provide, to our knowledge, the first genome-wide RNA sequencing study
comparing the transcriptome of canine CETL and IMD using archival lesional skin sam-
ples. As expected, T-cell neoplasia and T-cell-driven inflammation have different gene
expression profiles, as shown by the principal component analysis. Interestingly, a distinct
clustering among the IMD cases, namely panepidermal cytotoxic dermatitis (PCD) vs.
lupus erythematosus (LE) cases, was not visible, which is most likely due to a certain
pathogenetic heterogeneity among these cases, and is potentially influenced by the diverse
anatomic origin and cellular composition of the biopsy samples. We validated the dif-
ference in the expressions of selected genes on the mRNA and protein levels, and could
confirm significant differences between CETL and IMD, but not between PCD and LE cases.
Thus, we performed differential gene expression analysis and pathway analyses only by
comparing the ajor diseases, the CETL and the IMD group, respectively.
For the pathway analysis, we used two different enrichment analysis tools based on
three different databases (KEGG, GO, IPA) in order to have an internal validation. We
performed the enrichment analysis separately for up- and downregulated genes in CETL,
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as it has been shown that this approach can identify more relevant pathways, some of
which might be missed in an overall enrichment analysis [20].
Among genes upregulated in CETL, the top enriched pathways and GO terms in
all analyses included genes related to ribosomes and protein translation (eIF2 signaling,
ribosome, ribosomal subunits), and genes related to cell–matrix interactions (ILK signaling,
integrin signaling, focal adhesion). Ribosomal protein upregulation is described in several
types of cancer [40–44]. However, the underlying mechanism is largely unknown due
to the lack of functional analyses [41,43,44]. It remains open whether the upregulation
is a prerequisite or a consequence of neoplastic transformation. Ribosomal biogenesis is
also enriched in proliferating cells without having an active impact on carcinogenesis [45].
In contrast to many other cancer cells, T lymphocytes in CETL are usually not highly
proliferative, as shown by Fontaine et al. using Ki67 as a proliferation marker [2]. The
mitotic activity in our CETL cases was also low (Table S2), and was only slightly higher
than in the IMD group. As such, the proliferation is unlikely to be the sole explanation
for the higher ribosomal protein expression. Upregulated ribosomal biogenesis might
therefore be related to the neoplastic transformation of T lymphocytes.
The second molecular process enriched in CETL was the interaction between cells and
extracellular matrix (focal adhesion, ILK signaling and integrin signaling), encompassing
the mechanical connection as well as the signaling [46]. This molecular process includes a
number of integrin subunits, which are linked to several downstream cascades involved
in cell proliferation, differentiation, apoptosis and migration [47]. Dysregulated integrin
activity may contribute to tumor progression and metastasis formation [48]. A recent study
on canine melanocytic tumors described integrins to be important upstream regulators
favoring melanoma development [12].
Among genes with significantly lower expression in CETL, and which are thus up-
regulated in IMD, the enriched pathways included transmembrane receptor signaling in
conjunction with G-protein coupled receptors. This protein family with over 800 mem-
bers is the major class of sensory receptors, including receptors for chemokines, other
inflammatory mediators and neuroactive substances, and is important for the migration
of inflammatory and neoplastic immune cells [49,50]. In canine CETL, an upregulation
of CCR4 and CCR10 expression compared to normal skin has been described [51]. In
our study, CCR4 and other chemokine receptors had a significant lower expression in the
CETL group, which may be explained by the fact that CCR4 and CCR10 expression is
increased also under inflammatory conditions [49]. Here, the inclusion of normal canine
skin into our analyses would have improved the comparability of our results with those of
previous studies.
On the single gene level, we found 83 differentially expressed genes described previ-
ously in gene expression analyses of human CETL (Table S7). In contrast, we could not
find similarities to previous studies on canine CETL, although those veterinary studies
focused only on a selection of chemokines, chemokine receptors, cytokines and markers
for cytotoxicity analyzed by RT-qPCR. Moreover, they compared CETL to healthy skin
and blood, respectively, and not to inflammatory disease, explaining, at least partially, the
discrepancy [51,52]. In awareness of the differences between human and canine CETL, we
selected four genes with reported upregulations in human CETL, TCF7, IL2RB, CD5, and
ITGB7 for validation on the mRNA level by RT-qPCR. We focused on genes with higher
expressions in CETL, as our secondary aim was to identify potential biomarkers reliably
and easily excluding a T-cell-driven inflammatory process.
Transcription factor 7 (TCF7), also known as T-cell factor 1 (TCF1), is an essential
transcription factor of the WNT-signaling pathway. It is predominantly expressed in T
lymphocytes and is important for the T-cell development [53]. The TCF7 gene upregulation
was described in some of the uncommon human mycosis fungoides (MF) cases as exhibiting
an aggressive behavior [24]. Additionally, the protein expression of TCF7 was shown in
human peripheral T-cell lymphomas expressing markers of Th1 activation [54]. By RT-
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qPCR, we could verify significantly increased mRNA levels in the CETL group, and we
detected a higher percentage of TCF7-positive cells in the CETL group using IHC.
IL2RB is the gene encoding the interleukin-2 receptor (IL-2R) β subunit. Interleukin 2
(IL-2) and its receptor are critically involved in the control of T-cell growth [55]. IL-2Rα,
another subunit of the high affinity receptor, is known to be upregulated in activated T-cells
and in human Sézary syndrome, the leukemic form of MF [56,57]. While the expression
levels of IL-2Rβ and IL-2Rγ are lower in resting T-cells, IL-2Rβ expression in particular
is upregulated after T-cell activation [58]. In our study, IL2RB mRNA expression was
upregulated in the CETL group in both RNA sequencing and confirmatory RT-qPCR. This
upregulation might reflect a similar aberrant T-cell activation in canine CETL to that shown
in the human disease.
ITGB7 was selected because of its involvement in the enriched focal adhesion pathway.
Moreover, the protein encoded by this gene forms dimers with integrin αEβ7, which is
a described marker for epitheliotropism in human MF [59]. Our RT-qPCR results con-
firmed the significantly higher expression of ITGB7 in the CETL group discovered by
RNA sequencing.
CD5 encodes the T-cell glycogen receptor CD5, the loss of which is a criterion for the
diagnosis of a neoplastic process in early human MF [11]. Similar findings were described
for canine CETL using immunohistochemistry on cryosections [7]. In our study, CD5
expression was increased in the CETL group according to our RNA sequencing, which
is consistent with the results from human studies [25]. However, RT-qPCR analysis did
not confirm an increased CD5 mRNA expression in CETL cases. Investigations on protein
expression by IHC were not possible due to the lack of a functional antibody on canine
FFPE tissues [7].
In addition to these four genes selected due to their overlap with human CETL studies,
we selected ILK and FOXP3 for validation. ILK encodes the integrin-linked kinase, the
key protein of the upregulated ILK signaling pathway. ILK is a downstream enzyme in
integrin signaling, with further connections to the WNT pathway, thus playing a role
in cell adhesion, survival and cell cycle regulation [60]. Besides being upregulated in
several human epithelial cancer types, ILK has been reported as a survival factor in
human acute myelogenous leukemia, and as an important factor for T-cell trafficking and
survival [26–28,61]. The increased ILK expression detected by RNA sequencing could be
confirmed by RT-qPCR.
Although not significantly differentially expressed in our RNA-seq analysis, we inves-
tigated the expression of FOXP3, a transcription factor expressed in regulatory T-cells, by
RT-qPCR and IHC. We selected FOXP3, because regulatory T-cells were recently described
to play a role in several human skin diseases including MF [29–32]. The RT-qPCR results
accorded with the RNA sequencing. Surprisingly, immunohistochemistry revealed a signif-
icantly decreased percentage of FOXP3-positive T-cells in the CETL group. In human MF, a
reduced number of FOXP3-positive T-cells is associated with worse prognosis [30,32]. Our
findings would be in line with this human situation, as canine CETL has a poor prognosis
in most cases.
A limitation of this study is the use of FFPE tissue for RNA extraction, as formalin
fixation leads to nucleic acid crosslinking and RNA fragmentation [62]. In order to yield
the best possible RNA quality and quantity, we used an RNA extraction kit specifically
designed for FFPE tissue and a library preparation kit suitable for highly degraded RNA,
as specified by the manufacturers. Our transcriptome mapping percentage of 29.7% on
average is compatible with yields from previous RNA-seq studies using FFPE tissue
samples, and may be explained by the high amounts of conserved nuclear unspliced RNA
due to formalin fixation [13,62,63]. These studies nevertheless all confirmed that RNA
sequencing from FFPE tissue is possible and can produce biologically meaningful results.
Moreover, as the confirmatory diagnosis in veterinary medicine is routinely made by
histopathology on FFPE material, and the challenge of ambiguity between CETL and IMD
occurs with this sample type, it is reasonable to use this material for biomarker screening
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by RNA-seq. The RNA-seq data quality in our study can be regarded as appropriate since
our PCA plot appears adequate and gene expression differences could be confirmed by
RT-qPCR. Nevertheless, as low exonic read mapping may hinder the detection of genes
with low expression levels, one should consider increasing the sequencing depth when
using FFPE tissue samples for RNA-seq [62].
For the discovery of diagnostic biomarkers reliably discriminating ambiguous CETL
and IMD cases, the examination of a higher number of cases is needed. Furthermore,
additional limitations are based on the retrospective character of the study. First, most
dogs included had been treated with glucocorticoids and/or antibiotics. This may have
influenced the transcriptional profile of the biopsies. Second, the investigated lesions
may represent different stages (especially CETL cases), which may have an effect on the
transcriptional profiles. Third, biopsies originated from various anatomical locations, and
no site-matched non-lesional skin was included in the study, neither from dogs in the
study cohort, nor from additional control dogs. Site-matched samples could have helped in
filtering out site-specific background noise and potential differences in the gene expression
profiles. Non-lesional control tissue was unfortunately not considered during the study
design. Later on, the separate sequencing of normal skin samples would potentially have
resulted in major batch effects, making comparison with the initially sequenced samples
difficult to impossible [64]. A second sequencing experiment with additional normal skin
samples was unfortunately not possible, as there was not enough material of the primary
sample cases.
Despite these limitations, our study nevertheless provides new insights into the molec-
ular differences between CETL and IMD, and is thus a first unbiased and comprehensive
screening for potential biomarkers. Our DESeq dataset comprises hundreds of genes
expressed differentially between CETL and IMD cases, which may be used for future in-
vestigations into mRNA and/or protein expression differences in a larger archival sample
collection, or in a prospective study using fresh-frozen canine skin samples.
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425/12/2/160/s1, Table S1. Table 2 extended with clinical parameters of the study population,
Table S2. Histopathological parameters of the study population, Table S3. Summary of the raw
data analysis results of the samples submitted to RNA-seq, Table S4. Results of the differential
gene expression analysis, Table S5. List of enriched pathways and GO terms, respectively, among
genes with significantly higher expression in CETL samples resulting from enrichment analyses
with KOBAS 3.0 and IPA, Table S6. List of enriched pathways and GO terms, respectively, among
genes with significantly lower expression in CETL samples resulting from enrichment analyses with
KOBAS 3.0 and IPA, Table S7. Differentially expressed genes in our dataset previously described in
human cutaneous epitheliotropic lymphoma, Figure S1. Boxplot depicting the Cook’s distances of
genes across samples. Horizontal lines in the boxes represent the median (below 1 in all cases), boxes
include the interquartile range, and whiskers delimitate the whole range of values calculated per
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three different groups, Figure S3. Positive control lymph nodes used for immunohistochemistry.
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Appendix A
Western blot analysis showing cross-reactivity of the TCF7 antibody with the
canine orthologue.
Materials and Methods: In total, 90mg fresh frozen canine lymph node tissue was
lysed in 1ml RIPA lysis buffer (50 mM Tris/HCl pH 7.4; 1% NP-40; 0.5% Na-deoxycholate;
0.1% SDS; 150 mM NaCl, 2 nM EDTA, 50 mM NaF) containing complete protease inhibitor
cocktail (Roche, F. Hoffmann-La Roche Ltd., Basel, Switzerland) for 30 min on ice. It was
homogenized using TissueLyser (QIAGEN, Hombrechtikon, Switzerland) for 5 min and
cells were sonicated using Q700 Sonicator (Qsonica L.L.C, Newtown, CT, USA). After
a centrifugation step (12,000rpm for 20 min at 4 ◦C), the protein concentration of the
lysate was assessed using Pierce BCA assay kit (ThermoFisher Scientific, Reinach, Basel).
A 2X SDS sample buffer was added, then the lysate was boiled for 10 min at 95 ◦C.
Then 50µg total protein was loaded on a 12% SDS-PAGE and transferred to a PVDF
membrane (Immobilon-P PVDF Membrane, MERCK, Zug, Switzerland) for 1h at 100 V.
The membrane was blocked with 5% milk in TBS-T (100 mM Tris, pH 7.5, 0.9% NaCl,
0.05% Tween-20) for 1 h at room temperature and incubated with rabbit monoclonal
TCF7 antibody (1:1000 dilution in 5% skimmed milk, C.725.7, ThermoFisher Scientific,
Reinach, Switzerland) overnight at 4 ◦C. The membrane was rinsed twice with TBS-T and
incubated with a horseradish peroxidase-conjugated polyclonal goat anti-rabbit antibody
(1:2500, Cell Signaling Technologies, Leiden, Netherlands) in 5% skimmed milk for 1h at
room temperature. After 4 washing steps with TBS-T, the bound complex was visualized
using the chemiluminescent detection reagent (Amersham ECL Western blotting Detection
Reagent, GE Healthcare Europe GmbH, Glattbrugg, Switzerland) on the Fusion FX (Vilber,
Marne-la-Vallée, France). As a control for the protein content an additional blot was
performed in parallel using β-actin primary antibody (A5441, dilution 1:2000, MERCK, Zug,
Switzerland) and goat anti-mouse secondary antibody (1:2500, Cell Signaling Technologies,
Leiden, The Netherlands).
Results: The western blot with the β-actin antibody showed a clear band slightly below
45 kDa, indicating the expected molecular weight. The TCF7 antibody produced a band
that was weaker but also clear between 45 and 55kDa, which is slightly above the expected
molecular weight of 42 kDa. This result demonstrates a specific cross-reaction of the TCF7
antibody with the canine protein orthologue (Figure A1).
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